Predisposition, Genetic Clinical Trial
Official title:
The Informed Genetics Annotated Patient Registry: The iGAP Registry
This prospective and retrospective registry will evaluate the clinical effectiveness of Germline Genetic, Genomic, and other Biomarker testing results over time in different clinical populations, in order to shape guidelines for testing, patient management, and precision therapy.
Interest and knowledge about the genetics and biology of an individual's inherited risk of disease and progression of disease is growing. Physicians are increasing using tests and technology, including Germline Genetic, Genomic, and Biomarker Testing, to provide insight into a healthy individual's risk and an affected individual's disease characteristics, in order to provide individualized clinical treatments. However, many barriers to widespread and appropriate Germline Genetic, Genomic, and Biomarker Testing persist due to complex guidelines for use, varied quality and cost, rapid advances, and adequate understanding of appropriate implementation by medical professionals. The iGAP Registry is a multi-center ongoing database designed to capture information on disease risk assessment, Germline Genetic, Genomic, and Biomarker Testing, and their utilization and impact on treatment practices and outcomes to help determine, over time, the most effective use of testing in varied patient populations and to support the increased use of precision medicine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03472807 -
EXOme Rare Cancers in Children (EXOCARE)
|
N/A | |
| Completed |
NCT04848142 -
Psychosocial Impact of Disclosing Cancer Predisposition Genetic Testing Results During Childhood
|
||
| Completed |
NCT03982446 -
Germline Mutations in Pancreatic Adenocarcinoma
|